iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes

NCT03446638 · clinicaltrials.gov ↗

NA

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped administratively withdrawn

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: FDA-approved drug or combination of drugs
DRUG: FLAG induction
DRUG: 7 + 3 induction
DRUG: Low-dose cytarabine
OTHER: Supportive care alone
DEVICE: Computational biology simulations software

Sponsor

University of Florida

Collaborators

[object Object]
[object Object]